Management of clinical trials during the COVID-19 pandemic: Notice to clinical trial sponsors

During the pandemic, there may be more deviations from the established protocol. Despite this, it’s important to continue to protect patient safety and ensure data integrity. This notice addresses the concerns of clinical trial sponsors and Canadians.

Data and Resources

Additional Info

Field Value
Last Updated April 17, 2026, 17:51 (UTC)
Created April 17, 2026, 17:51 (UTC)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2021-05-06 00:00:00
open_canada_keywords {"fr": ["COVID-19", "pandémie", "gestion des essais cliniques", "avis aux promoteurs d'essais cliniques", "protocole établi", "sécurité des patients", "intégrité des données"], "en": ["COVID-19", "pandemic", "management of clinical trials", "notice to clinical trial sponsors", "established protocol", "patient safety", "data integrity"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr La gestion des essais cliniques pendant la pandémie de COVID-19 : Avis aux promoteurs d’essais cliniques
update_frequency as_needed